Expert rebuts Anthropic: Binder design is not a drug proxy
rapha_gl · x · 2026-08-19
Refuting Anthropic's claim that binder design is a 'useful proxy' for drug design, a CRISPR expert argues they are not equivalent. Anthropic had previously claimed Claude achieved a 22-35% binding success rate versus the industry average of 10-15%.
More from AGI Musings
- LLMs as the Internet's Immune System: Smoothing Anomalies and Stifling Innovation — tom_doerr · 2026-08-19
- AI Ethics Dilemmas: Paving Over Endangered Habitats for Data Centers? — binarybits · 2026-08-19
- AI Research Isn't Chess: It Requires Human Judgment on Conflicting Goals — binarybits · 2026-08-19
- Counterpoint: with aligned AGI, humans should delegate judgment like Carlsen delegating to a bot — binarybits · 2026-08-19
- Everyone dooms about Alphabet, yet the stock is fine — a case it's pivoting to infra — sebkrier · 2026-08-19
- The Next AlphaFold Won't Design Drugs — It Will Find the Right Targets — julia_kiseleva · 2026-08-19